A new clinical trial of innovative lung cancer therapy has launched

The “Dobrobut” medical network has opened patient enrollment for a Phase II clinical trial of first-line treatment for locally advanced or metastatic non-small cell non-squamous lung cancer (NSCLC) with a KRAS G12C mutation.

Within the trial, eligible patients will be able to receive modern targeted and immunotherapy treatment free of charge, which has already demonstrated effectiveness in international clinical practice.

Patients eligible to participate include those:

• with locally advanced non-small cell lung cancer (stages IIIb–IIIc) that is not suitable for surgical treatment or chemoradiotherapy;
• with metastatic lung cancer who have not yet received systemic treatment;
• with a confirmed non-squamous form of NSCLC;
• with a KRAS G12C mutation.

Participants will be randomly assigned to one of three treatment groups:

• chemotherapy + immunotherapy;
• an innovative KRAS G12C-targeted drug + immunotherapy;
• a KRAS G12C-targeted drug + immunotherapy + anti-EGFR therapy.

Study participants will receive access to leading treatment regimens that have shown efficacy in previous stages; free highly specialized medical care and support from the research team; free examinations предусмотрed by the protocol; and reimbursement of transportation costs to the clinical site in Kyiv, including travel from other cities.

Participation includes preliminary screening for eligibility. Each stage of treatment is carried out under the supervision of experienced specialists.

“Today, it is extremely important that Ukrainians have access to the most advanced treatment methods used worldwide. Innovative protocols, including KRAS G12C-targeted therapy, open new opportunities for patients who previously had limited treatment options. At ‘Dobrobut,’ we strive to ensure that our patients receive the same high-quality and modern treatment as patients in leading clinics in Europe and the United States. That is why participation in international clinical trials is our conscious contribution to expanding access to innovation and offering patients a chance for better treatment outcomes”, said Oleksandra Mashkevych, Chief Medical Director of the “Dobrobut” medical network.

Contact for scheduling an initial consultation:

Olha Zhmurko, Clinical Research Manager, +38 067 150 29 87, clinicaltrials@med.dobrobut.com